Ongoing trials with bevacizumab and other antiangiogenic agents in lung cancer

Clinical Lung Cancer

Volumn 9, Issue SUPPL. 2, 2008, Pages

  Dowlati, Afshin ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

AZD2171; Small Molecule inhibitors; Small cell lung cancer; Tracheoesophageal fistula

Indexed keywords

AFLIBERCEPT; AGATOLIMOD; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; CISPLATIN; DOCETAXEL; ENZASTAURIN; ERLOTINIB; ETOPOSIDE; GEMCITABINE; IMATINIB; IRINOTECAN; N ACETYLSARCOSYLGLYCYLVALYL DEXTRO ALLOISOLEUCYLTHREONYLNORVALYLISOLEUCYLARGINYLPROLINE ETHYLAMIDE; NAVELBINE; OXALIPLATIN; PACLITAXEL; PANOBINOSTAT; PEMETREXED; PLACEBO; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VATALANIB; XL 999;

ADVANCED CANCER; AGED; BRAIN METASTASIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG CLASSIFICATION; DRUG MECHANISM; DRUG SAFETY; GLIOBLASTOMA; HEMOPTYSIS; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; PROTEIN BLOOD LEVEL; REVIEW; SQUAMOUS CELL CARCINOMA; UNSPECIFIED SIDE EFFECT;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, PHARMACOLOGICAL; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; DRUG APPROVAL; HUMANS; LUNG NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PATIENT SELECTION; POPULATION GROUPS;

EID: 63849182876     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2008.s.011     Document Type: Article

References (19)

1. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007; 6:273-86.
2. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluoroura- cil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-42.
3. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevaci- zumab for non-small-cell lung cancer. N Engl J Med 2006; 355:2542-50.
4. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007; 25:4722-9.
5. ClinicalTrials.gov [Web site]. Available at: http://www.clinicaltrials. gov. Accessed: November 7, 2007.
6. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22:2184-91.
7. Ramalingam SS, Dahlberg SE, Langer CJ, et al. Outcomes for elderly, advanced- stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of eastern cooperative oncology group trial 4599. J Clin Oncol 2008; 26:60-5.
8. Manegold C, von Pawel J, Zatloukal P, et al. Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naive patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704. J Clin Oncol 2007; 25(18 suppl):388s (Abstract LBA7514).
9. Herbst RS, O'Neill VJ, Fehrenbacher L, et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol 2007; 25:4743-50.
10. Nieder C, Wiedenmann N, Andratschke N, et al. Current status of angiogenesis inhibitors combined with radiation therapy. Cancer Treat Rev 2006; 32:348-64.
11. Dowlati A, Gray R, Johnson D, et al. Cell adhesion molecules, vascular ednothelial growth factor, and basic fibroblast growth factor in patient with non-small cell lung cancer treated with chemotherapy with or without bevazicumab -- an Eastern Cooperative Oncology Study Group study. Clin Cancer Res 2008; 14:1407-12.
12. Salven P, Ruotsalainen T, Mattson K, et al. High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer. Int J Cancer 1998; 79:144-6.
13. Mall JW, Schwenk W, Philipp AW, et al. Serum vascular endothelial growth factor levels correlate better with tumour stage in small cell lung cancer than albumin, neuron-specific enolase or lactate dehydrogenase. Respirology 2002; 7:99-102.
14. Ruotsalainen T, Joensuu H, Mattson K, et al. High pretreatment serum concentration of basic fibroblast growth factor is a predictor of poor prognosis in small cell lung cancer. Cancer Epidemiol Biomarkers Prev 2002; 11:1492-5.
15. Litz, J, Sakuntala Warshamana-Greene G, Sulanke G, et al. The multi-targeted ki- nase inhibitor SU5416 inhibits small cell lung cancer growth and angiogenesis, in part by blocking Kit-mediated VEGF expression. Lung Cancer 2004; 46:283-91.
16. Sandler A, Szwaric S, Dowlati A, et al. A phase II study of cisplatin (P) plus eto- poside (E) plus bevacizumab (B) for previously untreated extensive stage small cell lung cancer (SCLC) (E3501): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2007; 25(18 suppl):400s (Abstract 7564).
17. Ready N, Dudek AZ, Wang XF, et al. CALGB 30306: a phase II study of cisplatin (C), irinotecan (I) and bevacizumab (B) for untreated extensive stage small cell lung cancer (ES-SCLC). J Clin Oncol 2007; 25(18 suppl):400s (Abstract 7563).
18. Lee SM, Woll PJ, James LE, et al. A phase III randomised, double blind, placebo controlled trial of etoposide/carboplatin with or without thalidomide in advanced small cell lung cancer (SCLC). J Thor Oncol 2007; 2(suppl 4):S306-S307 (Abstract PRS-04).
19. Arnold AM, Smylie M, Ding K, et al. Randomized phase II study of maintenance vandetanib (ZD6474) in small cell lung cancer (SCLC) patients who have a complete or partial response to induction therapy: NCIC CTG BR.20. J Clin Oncol 2007; 25(18 suppl):390s (Abstract 7522).